XML 37 R24.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration Agreements - Astellas Agreements - Additional Information (Detail) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 35 Months Ended | 45 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 31, 2016 | Apr. 30, 2006 | Jun. 30, 2005 | Jun. 30, 2018 | Jun. 30, 2018 | Dec. 31, 2012 | Dec. 31, 2010 | Feb. 28, 2009 | Feb. 28, 2009 | Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | $ 37,845 | $ 37,845 |  |  |  |  | $ 16,670
Astellas Agreement [Member] | Japan [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  |  |  |  |  |  |  | $ 40,100 |
Potential milestone payments |  |  | $ 132,500 |  |  |  |  |  |  |
Commercial sales milestone |  |  | 15,000 |  |  |  |  |  |  |
Milestones revenue | $ 22,500 |  |  |  |  |  |  |  |  |
Consideration associated with milestone included in transaction price |  |  |  | 15,000 |  |  |  |  |  |
Changes in revenue due to prior period adjustment |  |  |  | 14,900 | 14,900 |  |  |  |  |
Deferred revenue |  |  |  | $ 20,900 | 20,900 |  |  |  |  |
Astellas Agreement [Member] | Japan [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  | 22,500 |  |  |  |  |  |  |
Astellas Agreement [Member] | Japan [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  | $ 95,000 |  |  |  |  |  |  |
Astellas Agreement [Member] | Europe [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  |  |  |  |  |  | $ 320,000 |  |
Potential milestone payments |  | $ 425,000 |  |  |  |  |  |  |  |
Changes in revenue due to prior period adjustment |  |  |  |  | $ (200) |  |  |  |  |
Clinical development milestones |  |  |  |  |  | $ 50,000 | $ 40,000 |  |  |
Percentage of joint development costs committed to fund |  | 50.00% |  |  |  |  |  |  |  |
Additional consideration based on net sales description |  |  |  |  | Low 20% range |  |  |  |  |
Astellas Agreement [Member] | Europe [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  | $ 90,000 |  |  |  |  |  |  |  |
Astellas Agreement [Member] | Europe [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  | $ 335,000 |  |  |  |  |  |  |  |

X
- Definition The amount of additional consideration based on net sales of product as defined under a collaboration agreement. + References No definition available. + Details
Name: | fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to clinical development under the collaborative agreement. + References No definition available. + Details
Name: | fgen_ClinicalDevelopmentMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs. + References No definition available. + Details
Name: | fgen_PercentageOfFundingForCosts
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_PotentialMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586 + Details
Name: | us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |